30 Clinical evidence and Science Survival rates > 95% were also achieved in other clinical studies and retrospective analyses with CONELOG® implants (Tab. 4). CONELOG® implants with lengths of 7 mm were evaluated in two clinical studies: In a retrospective study Lorenz et al. 2019 (23) analyzed 30 CONELOG® implants in the posterior maxilla. Short implants were applied to avoid sinus augmentation procedures. After a mean follow-up of 5 years, the implant survival and success rate were 100% and the mean marginal bone loss was minimal (0.5 mm). Also, the peri-implant soft tissue showed no signs of inflammation (probing pocket depth, bleeding on probing). Therefore, the above-mentioned disadvantages of short implants seem not to have a negative influence on the implant success in the posterior area. A second study by Al-Sawaf et al. (2020) (24) focused on the crown-implant ratio topic and investigated the influence of splinted versus non-splinted fixed dental prostheses on short implants in the posterior mandible. The mean crown-implant ratio was 1.6 ± 0.3. At the 3 years follow-up examination no implants were lost and there was no loss of restoration of the 48 implants noted. The hard and soft tissue parameters in this randomized trial showed no significant differences between splinted and non-splinted superstructures. From loading to 3 years post-loading even a slight bone gain occurred in both groups (splinted: 0.1 ± 0.5 mm and non-splinted: 0.3 ± 0.8 mm). Both studies demonstrated stable peri-implant conditions around CONELOG® short implants in areas of limited vertical bone height and with increased crown-implant ratios and can be used as an alternative to augmentation measures in the posterior area. KEY TAKE OUTS: HIGH SUCCESS RATE OF THE CONELOG® IMPLANTS CONELOG® implants showed high success and survival rates in clinical studies comparable to the ones of CAMLOG® implants. Sharing the same implant surface (Promote®) and outer geometry equal success rates could be expected and were confirmed. The short implants with a length of 7 mm revealed promising clinical results in areas of limited vertical bone height and are a true alternative to bone augmentation measures in the posterior area. Authors Year Follow-up time (yrs) CONELOG® Implants Survival in % Ackermann et al. 2020 7 130 96.6 Cacaci et al. 2019 3 130 98.4 Moergel et al. 2021 5 52 95.4 Lorenz et al. 2019 7 30 100 Al-Sawaf et al. 2020 3 48 100 Fierravanti et al. (22) 2018 3 60 98.3 Tab. 4_Publications reporting mid-term and long-term survival rates of the CONELOG® Implant System CLINICAL EVIDENCE FOR CAMLOG® AND CONELOG® IMPLANTS
RkJQdWJsaXNoZXIy MTE0MzMw